Outlook Therapeutics (OTLK) Operating Income: 2015-2020
Historic Operating Income for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to -$10.0 million.
- Outlook Therapeutics' Operating Income rose 21.10% to -$10.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$36.8 million, marking a year-over-year decrease of 1.49%. This contributed to the annual value of -$71.7 million for FY2024, which is 34.97% down from last year.
- Latest data reveals that Outlook Therapeutics reported Operating Income of -$10.0 million as of Q3 2020, which was up 15.70% from -$11.9 million recorded in Q2 2020.
- In the past 5 years, Outlook Therapeutics' Operating Income ranged from a high of -$2.9 million in Q3 2017 and a low of -$22.0 million during Q2 2016.
- Over the past 3 years, Outlook Therapeutics' median Operating Income value was -$8.2 million (recorded in 2019), while the average stood at -$9.1 million.
- In the last 5 years, Outlook Therapeutics' Operating Income surged by 82.13% in 2017 and then tumbled by 326.49% in 2018.
- Quarterly analysis of 5 years shows Outlook Therapeutics' Operating Income stood at -$17.8 million in 2016, then spiked by 82.13% to -$3.2 million in 2017, then crashed by 222.58% to -$10.3 million in 2018, then rose by 20.21% to -$8.2 million in 2019, then rose by 21.10% to -$10.0 million in 2020.
- Its Operating Income stands at -$10.0 million for Q3 2020, versus -$11.9 million for Q2 2020 and -$6.8 million for Q1 2020.